| 臺大學術典藏 |
2021-01-28T01:06:18Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
|
Muro K.;Lordick F.;Tsushima T.;Pentheroudakis G.;Baba E.;Lu Z.;Cho B.C.;Nor I.M.;Ng M.;Chen L.-T.;Kato K.;Li J.;Ryu M.-H.;Wan Zamaniah W.I.;Yong W.-P.;Kun-Huei Yeh;Nakajima T.E.;Shitara K.;Kawakami H.;Narita Y.;Yoshino T.;Van Cutsem E.;Martinelli E.;Smyth E.C.;Arnold D.;Minami H.;Tabernero J.;Douillard J.-Y.; Muro K.; Lordick F.; Tsushima T.; Pentheroudakis G.; Baba E.; Lu Z.; Cho B.C.; Nor I.M.; Ng M.; Chen L.-T.; Kato K.; Li J.; Ryu M.-H.; Wan Zamaniah W.I.; Yong W.-P.; KUN-HUEI YEH; Nakajima T.E.; Shitara K.; Kawakami H.; Narita Y.; Yoshino T.; Van Cutsem E.; Martinelli E.; Smyth E.C.; Arnold D.; Minami H.; Tabernero J.; Douillard J.-Y. |
| 國立成功大學 |
2021 |
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
|
Park, K.;Tan, D.S.W.;Su, W.-C.;Cho, B.C.;Kim, S.-W.;Lee, K.H.;Wang, C.-C.;Seto, T.;Huang, D.C.-L.;Jung, H.H.;Hsu, M.-C.;Bogenrieder, T.;Lin, C.-C. |
| 國立成功大學 |
2021 |
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC
|
Herbst, R.S.;Garon, E.B.;Kim, D.-W.;Cho, B.C.;Gervais, R.;Perez-Gracia, J.L.;Han, J.-Y.;Majem, Majem M.;Forster, M.D.;Monnet, I.;Novello, S.;Gubens, M.A.;Boyer, M.;Su, W.-C.;Samkari, A.;Jensen, E.H.;Kobie, J.;Piperdi, B.;Baas, P. |
| 臺大學術典藏 |
2020-10-27T12:04:27Z |
Consensus recommendations for management of head and neck cancer in Asian countries: A review of international guidelines
|
Lu T; PEI-JEN LOU; Lin J.C; Kwong D; Hsieh W.S; Hu C; Guo Y; D'Cruz A; Lin T; Anand A.K; Atmakusuma D; Calaguas M.J; Chitapanarux I; Cho B.C; Goh B.C; Prabhash K; Sriuranpong V; Tang P; Vu V.V; Wahid I; Ang K.K; Chan A.T. |
| 臺大學術典藏 |
2020-08-13T06:33:31Z |
Enhancer remodeling and MicroRNA alterations are associated with acquired resistance to ALK inhibitors
|
Yun M.R.; Yun M.R.;Lim S.M.;Kim S.-K.;Choi H.M.;Pyo K.-H.;Kim S.K.;Lee J.M.;Lee Y.W.;Choi J.W.;Kim H.R.;Hong M.H.;Haam K.;Huh N.;Kim J.-H.;Kim Y.S.;Shim H.S.;Soo R.A.;Jin-Yuan Shih;Chih-Hsin Yang J.;Kim M.;Cho B.C.; Cho B.C.; Kim M.; Chih-Hsin Yang J.; JIN-YUAN SHIH; Soo R.A.; Shim H.S.; Kim Y.S.; Kim J.-H.; Lim S.M.; Kim S.-K.; Choi H.M.; Pyo K.-H.; Kim S.K.; Lee J.M.; Lee Y.W.; Choi J.W.; Kim H.R.; Hong M.H.; Haam K.; Huh N. |
| 臺大學術典藏 |
2020-08-13T06:33:31Z |
Enhancer remodeling and MicroRNA alterations are associated with acquired resistance to ALK inhibitors
|
Yun M.R.; Yun M.R.;Lim S.M.;Kim S.-K.;Choi H.M.;Pyo K.-H.;Kim S.K.;Lee J.M.;Lee Y.W.;Choi J.W.;Kim H.R.;Hong M.H.;Haam K.;Huh N.;Kim J.-H.;Kim Y.S.;Shim H.S.;Soo R.A.;Jin-Yuan Shih;Chih-Hsin Yang J.;Kim M.;Cho B.C.; Cho B.C.; Kim M.; Chih-Hsin Yang J.; JIN-YUAN SHIH; Soo R.A.; Shim H.S.; Kim Y.S.; Kim J.-H.; Lim S.M.; Kim S.-K.; Choi H.M.; Pyo K.-H.; Kim S.K.; Lee J.M.; Lee Y.W.; Choi J.W.; Kim H.R.; Hong M.H.; Haam K.; Huh N. |
| 臺大學術典藏 |
2020-05-26T09:27:20Z |
First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009
|
Soo R.A;Anderson B.O;Cho B.C;Chih-Hsin Yang;Liao M;Lim W.-T;Goldstraw P;Mok T.S.; Soo R.A; Anderson B.O; Cho B.C; CHIH-HSIN YANG; Liao M; Lim W.-T; Goldstraw P; Mok T.S. |
| 臺大學術典藏 |
2020-05-26T09:27:20Z |
First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009
|
Soo R.A;Anderson B.O;Cho B.C;Chih-Hsin Yang;Liao M;Lim W.-T;Goldstraw P;Mok T.S.; Soo R.A; Anderson B.O; Cho B.C; CHIH-HSIN YANG; Liao M; Lim W.-T; Goldstraw P; Mok T.S. |
| 臺大學術典藏 |
2020-05-26T09:27:17Z |
The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer
|
Cho B.C;Kim J.H;Soo R.A;Chih-Hsin Yang; Cho B.C; Kim J.H; Soo R.A; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:17Z |
The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer
|
Cho B.C;Kim J.H;Soo R.A;Chih-Hsin Yang; Cho B.C; Kim J.H; Soo R.A; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:29Z |
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
|
Havel L; Pauk N; Singh J; Murakami S; Garassino M.C; Cho B.-C; Kim J.-H; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray J.E; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo R.A; Huang Y; Wadsworth C; Dennis P.A; Rizvi N.A; Paz-Ares Rodriguez L; Novello S; Hiret S; Schmid P; Laack E; Califano R; Maemondo M; Kim S.-W; Chaft J; Vicente Baz D; Berghmans T; Kim D.-W; Surmont V; Reck M; Han J.-Y; Holgado Martin E; Belda Iniesta C; Oe Y; Chella A; Chopra A; Robinet G; Soto Parra H; Thomas M; Cheema P; Katakami N; Su W.-C; Kim Y.-C; Wolf J; Lee J.-S; Saka H; Milella M; Ramos Garcia I; Sibille A; Yokoi T; Kang E.J; Atagi S; Spaeth-Schwalbe E; Nishio M; Imamura F; Gabrail N; Veillon R; Derijcke S; Maeda T; Zylla D; Kubiak K; Santoro A; Uy M.N; Lucien Geater S; Italiano A; Kowalski D; Barlesi F; Chen Y.-M; Spigel D; Chewaskulyong B; Garcia Gomez R; Alvarez Alvarez R; CHIH-HSIN YANG; Hsia T.-C; Denis F; Sakai H; Vincent M; Goto K; Bosch-Barrera J; Weiss G; Canon J.-L; Scholz C; Aglietta M; Kemmotsu H; Csoszi T; Losonczy G; Price A; Anderson I; Iqbal M; Torri V; Juhasz E; Khanani S; Koubkova L; Levy B; Page R; Bocskei C; Crinò L; Einspahr D; Hagenstad C; Juat N; Overton L; Garrison M; Szalai Z; ATLANTIC Investigators; Azuma K; Bradbury P; Feld R; Chachoua A; Jassem J; Juergens R; Palmero Sanchez R; Malcolm A; Vrindavanam N; Kubota K; Waller C; Waterhouse D; Coudert B; Mark Z; Satouchi M; Chang G.-C; Herzmann C; Chaudhry A; Giridharan S; Hesketh P; Ikeda N; Boccia R; Iannotti N; Haigentz M; Reynolds J; Querol J; Nakagawa K; Sugawara S; Tan E.H; Hirashima T; Gettinger S; Kato T; Takeda K; Juan Vidal O; Mohn-Staudner A; Panwalkar A; Daniel D; Kobayashi K; Ladrera G.E.I; Schulte C; Sebastian M; Cernovska M; Coupkova H; Juat N;Hagenstad C;Einspahr D;Crin? L;Bocskei C;Page R;Levy B;Koubkova L;Khanani S;Juhasz E;Torri V;Iqbal M;Anderson I;Price A;Losonczy G;Csoszi T;Murakami S;Singh J;Pauk N;Havel L;Coupkova H;Cernovska M;Sebastian M;Schulte C;Ladrera G.E.I;Kobayashi K;Daniel D;Panwalkar A;Mohn-Staudner A;Juan Vidal O;Takeda K;Kato T;Gettinger S;Hirashima T;Tan E.H;Sugawara S;Nakagawa K;Querol J;Reynolds J;Haigentz M;Iannotti N;Boccia R;Ikeda N;Hesketh P;Giridharan S;Chaudhry A;Herzmann C;Chang G.-C;Satouchi M;Mark Z;Coudert B;Waterhouse D;Waller C;Kubota K;Vrindavanam N;Malcolm A;Palmero Sanchez R;Juergens R;Jassem J;Chachoua A;Feld R;Bradbury P;Azuma K;Kemmotsu H;Aglietta M;Scholz C;Canon J.-L;Weiss G;Bosch-Barrera J;Goto K;Vincent M;Sakai H;Denis F;Hsia T.-C;Chih-Hsin Yang;Alvarez Alvarez R;Garcia Gomez R;Chewaskulyong B;Spigel D;Chen Y.-M;Barlesi F;Kowalski D;Italiano A;Lucien Geater S;Uy M.N;Santoro A;Kubiak K;Zylla D;Maeda T;Derijcke S;Veillon R;Gabrail N;Imamura F;Nishio M;Spaeth-Schwalbe E;Atagi S;Kang E.J;Yokoi T;Sibille A;Ramos Garcia I;Milella M;Saka H;Lee J.-S;Wolf J;Kim Y.-C;Su W.-C;Katakami N;Atlantic Investigators;Szalai Z;Garrison M;Overton L;Cheema P;Thomas M;Soto Parra H;Robinet G;Chopra A;Chella A;Oe Y;Belda Iniesta C;Holgado Martin E;Han J.-Y;Reck M;Surmont V;Kim D.-W;Berghmans T;Vicente Baz D;Chaft J;Kim S.-W;Maemondo M;Califano R;Laack E;Schmid P;Hiret S;Novello S;Paz-Ares Rodriguez L;Rizvi N.A;Dennis P.A;Wadsworth C;Huang Y;Soo R.A;Park K;Wheatley-Price P;Bidoli P;Chouaid C;Powderly J;Gray J.E;Corral Jaime J;Lena H;Vansteenkiste J;Mazi?res J;Kim J.-H;Cho B.-C;Garassino M.C |
| 臺大學術典藏 |
2020-05-26T09:26:29Z |
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
|
Havel L; Pauk N; Singh J; Murakami S; Garassino M.C; Cho B.-C; Kim J.-H; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray J.E; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo R.A; Huang Y; Wadsworth C; Dennis P.A; Rizvi N.A; Paz-Ares Rodriguez L; Novello S; Hiret S; Schmid P; Laack E; Califano R; Maemondo M; Kim S.-W; Chaft J; Vicente Baz D; Berghmans T; Kim D.-W; Surmont V; Reck M; Han J.-Y; Holgado Martin E; Belda Iniesta C; Oe Y; Chella A; Chopra A; Robinet G; Soto Parra H; Thomas M; Cheema P; Katakami N; Su W.-C; Kim Y.-C; Wolf J; Lee J.-S; Saka H; Milella M; Ramos Garcia I; Sibille A; Yokoi T; Kang E.J; Atagi S; Spaeth-Schwalbe E; Nishio M; Imamura F; Gabrail N; Veillon R; Derijcke S; Maeda T; Zylla D; Kubiak K; Santoro A; Uy M.N; Lucien Geater S; Italiano A; Kowalski D; Barlesi F; Chen Y.-M; Spigel D; Chewaskulyong B; Garcia Gomez R; Alvarez Alvarez R; CHIH-HSIN YANG; Hsia T.-C; Denis F; Sakai H; Vincent M; Goto K; Bosch-Barrera J; Weiss G; Canon J.-L; Scholz C; Aglietta M; Kemmotsu H; Csoszi T; Losonczy G; Price A; Anderson I; Iqbal M; Torri V; Juhasz E; Khanani S; Koubkova L; Levy B; Page R; Bocskei C; Crinò L; Einspahr D; Hagenstad C; Juat N; Overton L; Garrison M; Szalai Z; ATLANTIC Investigators; Azuma K; Bradbury P; Feld R; Chachoua A; Jassem J; Juergens R; Palmero Sanchez R; Malcolm A; Vrindavanam N; Kubota K; Waller C; Waterhouse D; Coudert B; Mark Z; Satouchi M; Chang G.-C; Herzmann C; Chaudhry A; Giridharan S; Hesketh P; Ikeda N; Boccia R; Iannotti N; Haigentz M; Reynolds J; Querol J; Nakagawa K; Sugawara S; Tan E.H; Hirashima T; Gettinger S; Kato T; Takeda K; Juan Vidal O; Mohn-Staudner A; Panwalkar A; Daniel D; Kobayashi K; Ladrera G.E.I; Schulte C; Sebastian M; Cernovska M; Coupkova H; Juat N;Hagenstad C;Einspahr D;Crin? L;Bocskei C;Page R;Levy B;Koubkova L;Khanani S;Juhasz E;Torri V;Iqbal M;Anderson I;Price A;Losonczy G;Csoszi T;Murakami S;Singh J;Pauk N;Havel L;Coupkova H;Cernovska M;Sebastian M;Schulte C;Ladrera G.E.I;Kobayashi K;Daniel D;Panwalkar A;Mohn-Staudner A;Juan Vidal O;Takeda K;Kato T;Gettinger S;Hirashima T;Tan E.H;Sugawara S;Nakagawa K;Querol J;Reynolds J;Haigentz M;Iannotti N;Boccia R;Ikeda N;Hesketh P;Giridharan S;Chaudhry A;Herzmann C;Chang G.-C;Satouchi M;Mark Z;Coudert B;Waterhouse D;Waller C;Kubota K;Vrindavanam N;Malcolm A;Palmero Sanchez R;Juergens R;Jassem J;Chachoua A;Feld R;Bradbury P;Azuma K;Kemmotsu H;Aglietta M;Scholz C;Canon J.-L;Weiss G;Bosch-Barrera J;Goto K;Vincent M;Sakai H;Denis F;Hsia T.-C;Chih-Hsin Yang;Alvarez Alvarez R;Garcia Gomez R;Chewaskulyong B;Spigel D;Chen Y.-M;Barlesi F;Kowalski D;Italiano A;Lucien Geater S;Uy M.N;Santoro A;Kubiak K;Zylla D;Maeda T;Derijcke S;Veillon R;Gabrail N;Imamura F;Nishio M;Spaeth-Schwalbe E;Atagi S;Kang E.J;Yokoi T;Sibille A;Ramos Garcia I;Milella M;Saka H;Lee J.-S;Wolf J;Kim Y.-C;Su W.-C;Katakami N;Atlantic Investigators;Szalai Z;Garrison M;Overton L;Cheema P;Thomas M;Soto Parra H;Robinet G;Chopra A;Chella A;Oe Y;Belda Iniesta C;Holgado Martin E;Han J.-Y;Reck M;Surmont V;Kim D.-W;Berghmans T;Vicente Baz D;Chaft J;Kim S.-W;Maemondo M;Califano R;Laack E;Schmid P;Hiret S;Novello S;Paz-Ares Rodriguez L;Rizvi N.A;Dennis P.A;Wadsworth C;Huang Y;Soo R.A;Park K;Wheatley-Price P;Bidoli P;Chouaid C;Powderly J;Gray J.E;Corral Jaime J;Lena H;Vansteenkiste J;Mazi?res J;Kim J.-H;Cho B.-C;Garassino M.C |
| 臺大學術典藏 |
2020-05-26T09:26:27Z |
Enhancer remodeling and MicroRNA alterations are associated with acquired resistance to ALK inhibitors
|
Kim S.K; Lee J.M; Lee Y.W; Choi J.W; Kim H.R; Hong M.H; Haam K; Huh N; Kim J.-H; Kim Y.S; Shim H.S; Soo R.A; Shih J.-Y; Chih-Hsin CHIH-HSIN YANG; Kim M; Cho B.C.; Cho B.C.;Kim M;Chih-Hsin Chih-Hsin Yang;Shih J.-Y;Soo R.A;Shim H.S;Kim Y.S;Kim J.-H;Huh N;Haam K;Hong M.H;Kim H.R;Choi J.W;Lee Y.W;Lee J.M;Kim S.K;Pyo K.-H;Choi H.M;Kim S.-K;Lim S.M;Yun M.R; Yun M.R; Lim S.M; Kim S.-K; Choi H.M; Pyo K.-H |
| 臺大學術典藏 |
2020-05-26T09:26:27Z |
Enhancer remodeling and MicroRNA alterations are associated with acquired resistance to ALK inhibitors
|
Kim S.K; Lee J.M; Lee Y.W; Choi J.W; Kim H.R; Hong M.H; Haam K; Huh N; Kim J.-H; Kim Y.S; Shim H.S; Soo R.A; Shih J.-Y; Chih-Hsin CHIH-HSIN YANG; Kim M; Cho B.C.; Cho B.C.;Kim M;Chih-Hsin Chih-Hsin Yang;Shih J.-Y;Soo R.A;Shim H.S;Kim Y.S;Kim J.-H;Huh N;Haam K;Hong M.H;Kim H.R;Choi J.W;Lee Y.W;Lee J.M;Kim S.K;Pyo K.-H;Choi H.M;Kim S.-K;Lim S.M;Yun M.R; Yun M.R; Lim S.M; Kim S.-K; Choi H.M; Pyo K.-H |
| 臺大學術典藏 |
2020-05-26T09:26:18Z |
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer
|
Yun M.R;Choi H.M;Lee Y.W;Joo H.S;Park C.W;Choi J.W;Kim D.H;Kang H.N;Pyo K.-H;Shin E.J;Shim H.S;Soo R.A;Chih-Hsin Yang;Lee S.S;Chang H;Kim M.H;Hong M.H;Kim H.R;Cho B.C.; Yun M.R; Choi H.M; Lee Y.W; Joo H.S; Park C.W; Choi J.W; Kim D.H; Kang H.N; Pyo K.-H; Shin E.J; Shim H.S; Soo R.A; CHIH-HSIN YANG; Lee S.S; Chang H; Kim M.H; Hong M.H; Kim H.R; Cho B.C. |
| 臺大學術典藏 |
2020-05-26T09:26:18Z |
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer
|
Yun M.R;Choi H.M;Lee Y.W;Joo H.S;Park C.W;Choi J.W;Kim D.H;Kang H.N;Pyo K.-H;Shin E.J;Shim H.S;Soo R.A;Chih-Hsin Yang;Lee S.S;Chang H;Kim M.H;Hong M.H;Kim H.R;Cho B.C.; Yun M.R; Choi H.M; Lee Y.W; Joo H.S; Park C.W; Choi J.W; Kim D.H; Kang H.N; Pyo K.-H; Shin E.J; Shim H.S; Soo R.A; CHIH-HSIN YANG; Lee S.S; Chang H; Kim M.H; Hong M.H; Kim H.R; Cho B.C. |
| 臺大學術典藏 |
2020-05-25T07:35:14Z |
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
|
Yang J.C.-H.; Yang Z; Overend P; Kao S; Goldman J.W; Su W.-C; Natale R; Rabbie S; Harrop B; John T; Kim H.R; Chia-Chi Lin; Kim T.M; Ahn J.-S; Lee J.S; Kim S.-W; Cho B.C; Kim D.-W; Ahn M.-J |
| 臺大學術典藏 |
2020-05-25T07:35:09Z |
Combination of the S49076 with gefitinib in NSCLC patients progressing on EGFR-TKI and harboring MET/AXL dysregulation
|
Viteri S; Chang G.-C; Chiari R; Cho B.C; Ciardiello F; Curigliano G; Hida T; Lee D.H; Lim W.T.D; Chia-Chi Lin; Martinez A; Murakami H; Natsume I; Nishio M; Paz-Ares L; Soo R.A; Cattan V; Gandossi E; Heck H; Park K. |
| 臺大學術典藏 |
2020-05-25T07:35:06Z |
Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2
|
Barlesi F; Drilon A; De Braud F; Cho B.C; Ahn M.J; Siena S; Krebs M.G; Chia-Chi Lin; John T; Tan D.S.W; Seto T; Dziadziuszko R; Arkenau H.-T; Rolfo C; Wolf J; Ye C; Riehl T; Eng S; Doebele R.C. |
| 臺大學術典藏 |
2020-05-25T07:35:02Z |
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1�V2 trials
|
Rolfo C; de Braud F; Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs M.G; Shaw A.T; Doebele R.C.;Wilson T.R;Eng S;Johnson A;Cui N;Simmons B;Chow-Maneval E;Riehl T;Prenen H;Tan D.S.W;Chia-Chi Lin;Murakami H;Otterson G.A;Chung C.H;Chae Y.K;Li Y.-C;Ohe Y;Kim S.-W;Arkenau H.-T;Karapetis C.S;Goto K;John T;Chiu C.-H;Patel M.R;Cho B.C;Seto T;Wolf J;Ahn M.-J;Rolfo C;de Braud F;Shaw A.T;Krebs M.G;Barlesi F;Dziadziuszko R;Siena S;Drilon A; Ahn M.-J; Wolf J; Seto T; Cho B.C; Patel M.R; Chiu C.-H; John T; Goto K; Karapetis C.S; Arkenau H.-T; Kim S.-W; Ohe Y; Li Y.-C; Chae Y.K; Chung C.H; Otterson G.A; Murakami H; Chia-Chi Lin; Tan D.S.W; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson T.R; Doebele R.C. |
| 臺大學術典藏 |
2020-05-25T07:35:02Z |
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1�V2 trials
|
Rolfo C; de Braud F; Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs M.G; Shaw A.T; Doebele R.C.;Wilson T.R;Eng S;Johnson A;Cui N;Simmons B;Chow-Maneval E;Riehl T;Prenen H;Tan D.S.W;Chia-Chi Lin;Murakami H;Otterson G.A;Chung C.H;Chae Y.K;Li Y.-C;Ohe Y;Kim S.-W;Arkenau H.-T;Karapetis C.S;Goto K;John T;Chiu C.-H;Patel M.R;Cho B.C;Seto T;Wolf J;Ahn M.-J;Rolfo C;de Braud F;Shaw A.T;Krebs M.G;Barlesi F;Dziadziuszko R;Siena S;Drilon A; Ahn M.-J; Wolf J; Seto T; Cho B.C; Patel M.R; Chiu C.-H; John T; Goto K; Karapetis C.S; Arkenau H.-T; Kim S.-W; Ohe Y; Li Y.-C; Chae Y.K; Chung C.H; Otterson G.A; Murakami H; Chia-Chi Lin; Tan D.S.W; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson T.R; Doebele R.C. |
| 臺大學術典藏 |
2020-05-25T07:35:02Z |
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-�] and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial
|
Paz-Ares L; Kim T.M; Vicente D; Felip E; Lee D.H; Lee K.H; Chia-Chi Lin; Flor M.J; Di Nicola M; Alvarez R.M; Dussault I; Helwig C; Ojalvo L.S; Gulley J.L; Cho B.C. |
| 臺大學術典藏 |
2020-04-28T07:25:09Z |
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
|
Kato K.; Cho B.C.; Takahashi M.; Okada M.; Lin C.-Y.; Chin K.; Kadowaki S.; Ahn M.-J.; Hamamoto Y.; Doki Y.; Yen C.-C.; Kubota Y.; Kim S.-B.; CHIH-HUNG HSU; Holtved E.; Xynos I.; Kodani M.; Kitagawa Y.; Kato K.;Cho B.C.;Takahashi M.;Okada M.;Lin C.-Y.;Chin K.;Kadowaki S.;Ahn M.-J.;Hamamoto Y.;Doki Y.;Yen C.-C.;Kubota Y.;Kim S.-B.;Chih-Hung Hsu;Holtved E.;Xynos I.;Kodani M.;Kitagawa Y. |
| 臺大學術典藏 |
2020-04-28T07:25:09Z |
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
|
Kato K.; Cho B.C.; Takahashi M.; Okada M.; Lin C.-Y.; Chin K.; Kadowaki S.; Ahn M.-J.; Hamamoto Y.; Doki Y.; Yen C.-C.; Kubota Y.; Kim S.-B.; CHIH-HUNG HSU; Holtved E.; Xynos I.; Kodani M.; Kitagawa Y.; Kato K.;Cho B.C.;Takahashi M.;Okada M.;Lin C.-Y.;Chin K.;Kadowaki S.;Ahn M.-J.;Hamamoto Y.;Doki Y.;Yen C.-C.;Kubota Y.;Kim S.-B.;Chih-Hung Hsu;Holtved E.;Xynos I.;Kodani M.;Kitagawa Y. |
| 國立成功大學 |
2020 |
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
|
Sequist, L.V.;Han, J.-Y.;Ahn, M.-J.;Cho, B.C.;Yu, H.;Kim, S.-W.;Yang, J.C.-H.;Lee, J.S.;Su, W.-C.;Kowalski, D.;Orlov, S.;Cantarini, M.;Verheijen, R.B.;Mellemgaard, A.;Ottesen, L.;Frewer, P.;Ou, X.;Oxnard, G. |
